Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Chronic lymphocytic leukemia therapy: new targeted therapies on the way
Candida Vitale
,
Jan A. Burger
Leukemia
Research output
:
Contribution to journal
›
Review article
›
peer-review
13
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Chronic lymphocytic leukemia therapy: new targeted therapies on the way'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
New Drug Targets
100%
Chronic Lymphocytic Leukemia
100%
Leukemia Therapy
100%
B-cell Receptor Signaling
42%
New Drugs
28%
Leukemia Patients
14%
Clinical Data
14%
High Risk
14%
CD20
14%
Clinical Efficacy
14%
Mechanism of Action
14%
New Agents
14%
Chronic Lymphocytic Leukemia Cells
14%
Preclinical Data
14%
Cell Surface
14%
Expert Opinion
14%
Targeted Agents
14%
PubMed
14%
Chemoimmunotherapy
14%
Relapsed Disease
14%
Tissue Microenvironment
14%
Armamentarium
14%
Ibrutinib
14%
Idelalisib
14%
Area Cover
14%
Late Development
14%
Side Effect Profile
14%
Direct Targeting
14%
Peer-reviewed Articles
14%
International Meeting
14%
Heterogeneous Mechanism
14%
New Targeted Drugs
14%
Venetoclax
14%
BCL-2 Inhibitor
14%
Obinutuzumab
14%
Microenvironment Cells
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
B Lymphocyte Receptor
37%
Diseases
12%
Immunotherapy
12%
Idelalisib
12%
Ibrutinib
12%
Obinutuzumab
12%
Venetoclax
12%
Side Effect
12%
Pathogenesis
12%